Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of antiviral therapeutics. The company's lead product candidate, AT-527, is in Phase II clinical trial for the treatment of COVID-19. Atea also develops AT-752, AT-777, AT-787, and AT-281 for the treatment of various viral infections, including dengue, yellow fever, Zika virus, and coronaviridae viral infection. Additionally, the company has a license agreement with Merck & Co, Inc. for the development and commercialization of ruzasvir, an oral NS5A inhibitor for the treatment of chronic HCV infection.

Products

• AT-527 for COVID-19 treatment

• AT-752 for dengue treatment

• AT-777 for viral infection treatment

• AT-787 for HCV treatment

• AT-281 for RNA viral infection treatment

• Ruzasvir for chronic HCV infection treatment